Why Labcorp Holdings (LH) Is Up 7.7% After Expanding Advanced At-Home and Blood-Based Diagnostics

In late June 2026, Labcorp highlighted new peer-reviewed evidence supporting its MVX and NIS2+ blood tests for assessing metabolic liver disease risk and announced nationwide U.S. launch of ColoSense, an FDA-approved, RNA-based at-home colorectal cancer screening test now covered for eligible Medicare beneficiaries.
Together, these tools suggest Labcorp is deepening its role in simplifying early detection of liver and colorectal disease through less invasive, broadly accessible...